Cargando…
Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer
Increased detection of plasma lysophosphatidic acid (LPA) has been proposed as a potential diagnostic biomarker in ovarian cancer, but inconsistency exists in these reports. It has been shown that LPA can undergo an artificial increase during sample processing and analysis, which has not been accoun...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521627/ https://www.ncbi.nlm.nih.gov/pubmed/30979045 http://dx.doi.org/10.3390/cancers11040520 |
_version_ | 1783419001803636736 |
---|---|
author | Yagi, Tsukasa Shoaib, Muhammad Kuschner, Cyrus E. Nishikimi, Mitsuaki Becker, Lance B. Lee, Annette T. Kim, Junhwan |
author_facet | Yagi, Tsukasa Shoaib, Muhammad Kuschner, Cyrus E. Nishikimi, Mitsuaki Becker, Lance B. Lee, Annette T. Kim, Junhwan |
author_sort | Yagi, Tsukasa |
collection | PubMed |
description | Increased detection of plasma lysophosphatidic acid (LPA) has been proposed as a potential diagnostic biomarker in ovarian cancer, but inconsistency exists in these reports. It has been shown that LPA can undergo an artificial increase during sample processing and analysis, which has not been accounted for in ovarian cancer research. The aim of this study is to provide a potential explanation about how the artificial increase in LPA may have interfered with previous LPA analysis in ovarian cancer research. Using an established LC-MS method, we measured LPA and other lysophospholipid levels in plasma obtained from three cohorts of patients: non-cancer controls, patients with benign ovarian tumors, and those with ovarian cancer. We did not find the LPA level to be higher in cancer samples. To understand this inconsistency, we observed that LPA content changed more significantly than other lysophospholipids as a function of plasma storage time while frozen. Additionally, only LPA was found to be adversely impacted by incubation time depending on the Ethylenediaminetetraacetic acid (EDTA) concentration used during blood drawing. We also show that the inhibition of autotaxin effectively prevented artificial LPA generation during incubation at room temperature. Our data suggests that the artificial changes in LPA content may contribute to the discrepancies reported in literature. Any future studies planning to measure plasma LPA should carefully design the study protocol to consider these confounding factors. |
format | Online Article Text |
id | pubmed-6521627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65216272019-05-31 Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer Yagi, Tsukasa Shoaib, Muhammad Kuschner, Cyrus E. Nishikimi, Mitsuaki Becker, Lance B. Lee, Annette T. Kim, Junhwan Cancers (Basel) Article Increased detection of plasma lysophosphatidic acid (LPA) has been proposed as a potential diagnostic biomarker in ovarian cancer, but inconsistency exists in these reports. It has been shown that LPA can undergo an artificial increase during sample processing and analysis, which has not been accounted for in ovarian cancer research. The aim of this study is to provide a potential explanation about how the artificial increase in LPA may have interfered with previous LPA analysis in ovarian cancer research. Using an established LC-MS method, we measured LPA and other lysophospholipid levels in plasma obtained from three cohorts of patients: non-cancer controls, patients with benign ovarian tumors, and those with ovarian cancer. We did not find the LPA level to be higher in cancer samples. To understand this inconsistency, we observed that LPA content changed more significantly than other lysophospholipids as a function of plasma storage time while frozen. Additionally, only LPA was found to be adversely impacted by incubation time depending on the Ethylenediaminetetraacetic acid (EDTA) concentration used during blood drawing. We also show that the inhibition of autotaxin effectively prevented artificial LPA generation during incubation at room temperature. Our data suggests that the artificial changes in LPA content may contribute to the discrepancies reported in literature. Any future studies planning to measure plasma LPA should carefully design the study protocol to consider these confounding factors. MDPI 2019-04-11 /pmc/articles/PMC6521627/ /pubmed/30979045 http://dx.doi.org/10.3390/cancers11040520 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yagi, Tsukasa Shoaib, Muhammad Kuschner, Cyrus E. Nishikimi, Mitsuaki Becker, Lance B. Lee, Annette T. Kim, Junhwan Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title | Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title_full | Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title_fullStr | Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title_full_unstemmed | Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title_short | Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer |
title_sort | challenges and inconsistencies in using lysophosphatidic acid as a biomarker for ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521627/ https://www.ncbi.nlm.nih.gov/pubmed/30979045 http://dx.doi.org/10.3390/cancers11040520 |
work_keys_str_mv | AT yagitsukasa challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT shoaibmuhammad challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT kuschnercyruse challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT nishikimimitsuaki challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT beckerlanceb challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT leeannettet challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer AT kimjunhwan challengesandinconsistenciesinusinglysophosphatidicacidasabiomarkerforovariancancer |